2024
A Review of Dextromethorphan-Quinidine for the Treatment of Agitation in Dementia.
Khan A, Murphy K, Tampi R. A Review of Dextromethorphan-Quinidine for the Treatment of Agitation in Dementia. The Primary Care Companion For CNS Disorders 2024, 26 PMID: 39546373, DOI: 10.4088/pcc.24nr03737.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsFull-text reviewDextromethorphan-quinidineTreatment of agitationDementia-related agitationAPA PsycInfoCase reportCochrane CollaborationAbstracted dataDementiaTreatment settingsDuration of treatmentPatient diagnosisPatient populationSymptom responseTreatment doseEnglish languageQualitative analysisAuthor affiliationTreatment studiesPsycINFOSymptomsTreatmentDextromethorphanPatients
2023
Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinib
2022
Using Daily Ratings to Examine Treatment Dose and Response in Cognitive Behavioral Therapy for Chronic Pain: A Secondary Analysis of the Co-Operative Pain Education and Self-Management Clinical Trial
MacLean R, Buta E, Higgins D, Driscoll M, Edmond S, LaChappelle K, Ankawi B, Krein S, Piette J, Heapy A. Using Daily Ratings to Examine Treatment Dose and Response in Cognitive Behavioral Therapy for Chronic Pain: A Secondary Analysis of the Co-Operative Pain Education and Self-Management Clinical Trial. Pain Medicine 2022, 24: 846-854. PMID: 36484691, PMCID: PMC10250557, DOI: 10.1093/pm/pnac192.Peer-Reviewed Original ResearchConceptsPain intensityCognitive behavioral therapyCBT-CPChronic painTreatment responseDaily stepsSecondary analysisBehavioral therapyMeaningful changeChronic back painStrong evidence baseBack painPain educationTreatment weekClinical trialsNoninferiority trialTreatment benefitOutcome measuresWeek 4Treatment doseWeek 2Baseline weekMost respondersSurvival analysisStep count
2021
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. Npj Breast Cancer 2021, 7: 60. PMID: 34040000, PMCID: PMC8154902, DOI: 10.1038/s41523-021-00270-4.Peer-Reviewed Original ResearchHeterogeneous cancer cell populationsCancer cell populationsTriple-negative breast cancerSingle-cell RNA sequencingCell populationsFitness advantageRNA sequencingMDA-MB-231 TNBC cellsDrug resistanceMechanisms of resistanceVitro screening assaysClonal dynamicsTNBC cellsScreening assaysResistant clonesPatterns of resistanceConcomitant treatmentTherapy combinationsBreast cancerClinical studiesTreatment doseTreatment scheduleBarcodesSequencingTreatment
2018
Predictors of Participation in a Nonpharmacological Intervention for Chronic Back Pain
Higgins DM, LaChappelle KM, Serowik KL, Driscoll MA, Lee A, Heapy AA. Predictors of Participation in a Nonpharmacological Intervention for Chronic Back Pain. Pain Medicine 2018, 19: s76-s83. PMID: 30753730, DOI: 10.1093/pm/pny077.Peer-Reviewed Original ResearchConceptsChronic back painPredictors of enrollmentCBT-CPBack painCognitive behavioral therapyEligible patientsMost patientsChronic painPain careEligible participantsPredictors of participationNonpharmacological interventionsNoninferiority trialMedical CenterDuration of participationTreatment doseTrial screeningPatientsPainBehavioral therapyOpioidsRegression analysisEnrollmentPredictorsDose
2016
Predicting treatment related imaging changes (TRICs) after radiosurgery for brain metastases using treatment dose and conformality metrics.
Taylor BF, Knisely JP, Qian JM, Yu JB, Chiang VL. Predicting treatment related imaging changes (TRICs) after radiosurgery for brain metastases using treatment dose and conformality metrics. Journal Of Radiosurgery And SBRT 2016, 4: 53-60. PMID: 29296426, PMCID: PMC5658837.Peer-Reviewed Original ResearchTreatment-related imaging changesPrescription isodose volumeConformity indexStereotactic radiosurgeryTumor volumeGamma Knife stereotactic radiosurgeryRadiation dose volumeSmall-volume lesionsPaddick conformity indexPost-treatment periodBrain metastasesAdditional patientsImaging changesDifferent post-treatment periodsTransient enlargementTreatment doseIsodose volumeRadiographic lesionsVolume lesionsClinical decisionDose volumeMetastasisTreatment factorsMonthsMonth period
2011
A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases
Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases. American Journal Of Neuroradiology 2011, 32: 1885-1892. PMID: 21920854, PMCID: PMC7966021, DOI: 10.3174/ajnr.a2668.Peer-Reviewed Original ResearchConceptsBrain metastasesMedian survivalMetastatic lesionsLesion sizeMost metastatic lesionsMR imaging changesPercent of lesionsInitial treatment volumeSystemic cancer therapyInitial lesion sizeIntracranial metastatic lesionsGK-SRSLesional responsePatient demographicsRadiographic responseInitial treatmentImaging changesMale sexTumor sizeLesion volumeStereotactic radiosurgeryTreatment dosePatientsLesionsRadiosurgery
2005
Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders
Jou R, Handen B, Hardan A. Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychopharmacology 2005, 15: 325-330. PMID: 15910217, DOI: 10.1089/cap.2005.15.325.Peer-Reviewed Original ResearchConceptsConners' Parent Rating ScalePervasive developmental disorderConcomitant medicationsClinical Global Impression ScaleTolerability of atomoxetinePlacebo-controlled studyGlobal Impression ScaleGlobal improvement itemSevere mood swingsDevelopmental disordersCPRS subscaleMost patientsClinic registryRetrospective studyImpression ScaleTreatment responseTreatment doseClinical informationPatientsAtomoxetineSecondary symptomsParent Rating ScaleMood swingsRating ScaleRetrospective assessment
1998
Internal Validity of Project MATCH Treatments: Discriminability and Integrity
Carroll K, Connors G, Cooney N, DiClemente C, Donovan D, Kadden R, Longabaugh R, Rounsaville B, Wirtz P, Zweben A. Internal Validity of Project MATCH Treatments: Discriminability and Integrity. Journal Of Consulting And Clinical Psychology 1998, 66: 290-303. PMID: 9583332, DOI: 10.1037/0022-006x.66.2.290.Peer-Reviewed Original ResearchConceptsMotivational enhancement therapyCognitive-behavioral treatmentProject MATCHDay hospital treatmentPatient-treatment interactionsAlcoholics Anonymous (AA) involvementInternal validityStudy treatmentHospital treatmentIntensive treatmentTreatment doseAlcohol-dependent participantsIntensive inpatientAlcoholism treatmentEnhancement therapyNonspecific aspectsTherapeutic allianceTreatmentOutpatientsParticipantsManual guidelinesHigh levelsInpatientsTherapyAftercare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply